BMS ponders sales cuts due to Pargluva delay
Facing the reality that diabetes drug Pargluva (muraglitazar) won’t be available for near-term promotion, Bristol-Myers Squibb is prepared to reduce ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.